Literature DB >> 30568007

Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy.

Rianne J M Goselink1, Karlien Mul2, Caroline R van Kernebeek2, Richard J L F Lemmers2, Silvère M van der Maarel2, Tim H A Schreuder2, Corrie E Erasmus2, George W Padberg2, Jeffrey M Statland2, Nicol C Voermans2, Baziel G M van Engelen2.   

Abstract

OBJECTIVE: To assess the relation between age at onset and disease severity in facioscapulohumeral muscular dystrophy (FSHD).
METHODS: In this prospective cross-sectional study, we matched adult patients with FSHD with an early disease onset with 2 sex-matched FSHD control groups with a classic onset; the first group was age matched, and the second group was disease duration matched. Genetic characteristics, muscle performance, respiratory functioning, hearing loss, vision loss, epilepsy, educational level, and work status were compared with the 2 control groups.
RESULTS: Twenty-eight patients with early-onset FSHD were age (n = 28) or duration (n = 27) matched with classic-onset patients. Patients with early-onset FSHD had more severe muscle weakness (mean FSHD clinical score 11 vs 5 in the age-matched and 9 in the duration-matched group, p < 0.05) and a higher frequency of wheelchair dependency (57%, 0%, and 30%, respectively, p < 0.05). In addition, systemic features were more frequent in early-onset FSHD, most important, hearing loss, decreased respiratory function and spinal deformities. There was no difference in work status. Genetically, the shortest D4Z4 repeat arrays (2-3 units) were found exclusively in the early-onset group, and the largest repeat arrays (8-9 units) were found only in the classic-onset groups. De novo mutations were more frequent in early-onset patients (46% vs 4%).
CONCLUSIONS: Patients with early-onset FSHD more often have severe muscle weakness and systemic features. The disease severity is greater than in patients with classic-onset FSHD who are matched for disease duration, suggesting that the progression is faster in early-onset patients.
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30568007      PMCID: PMC6345117          DOI: 10.1212/WNL.0000000000006819

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular dystrophy.

Authors:  Petra G M van Overveld; Richard J F L Lemmers; Lodewijk A Sandkuijl; Leo Enthoven; Sara T Winokur; Floor Bakels; George W Padberg; Gert-Jan B van Ommen; Rune R Frants; Silvère M van der Maarel
Journal:  Nat Genet       Date:  2003-11-23       Impact factor: 38.330

2.  A unifying genetic model for facioscapulohumeral muscular dystrophy.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Rinse Klooster; Sabrina Sacconi; Pilar Camaño; Johannes G Dauwerse; Lauren Snider; Kirsten R Straasheijm; Gert Jan van Ommen; George W Padberg; Daniel G Miller; Stephen J Tapscott; Rabi Tawil; Rune R Frants; Silvère M van der Maarel
Journal:  Science       Date:  2010-08-19       Impact factor: 47.728

3.  Subclinical cardiac involvement in patients with facioscapulohumeral muscular dystrophy.

Authors:  Fabio Galetta; Ferdinando Franzoni; Roberto Sposito; Yvonne Plantinga; Francesca Romana Femia; Fabio Galluzzi; Anna Rocchi; Gino Santoro; Gabriele Siciliano
Journal:  Neuromuscul Disord       Date:  2005-04-21       Impact factor: 4.296

4.  Infantile facioscapulohumeral muscular dystrophy revisited: Expansion of clinical phenotypes in patients with a very short EcoRI fragment.

Authors:  Tai-Heng Chen; Yu-Hung Lai; Pei-Lun Lee; Jong-Hau Hsu; Kanako Goto; Yukiko K Hayashi; Ichizo Nishino; Chin-Wen Lin; Hsiang-Hung Shih; Chao-Ching Huang; Wen-Chen Liang; Wen-Fu Wang; Yuh-Jyh Jong
Journal:  Neuromuscul Disord       Date:  2013-02-21       Impact factor: 4.296

5.  Severe phenotype in infantile facioscapulohumeral muscular dystrophy.

Authors:  Lars Klinge; Michelle Eagle; Irene D Haggerty; Catherine E Roberts; Volker Straub; Kate M Bushby
Journal:  Neuromuscul Disord       Date:  2006-08-24       Impact factor: 4.296

6.  A standardized clinical evaluation of patients affected by facioscapulohumeral muscular dystrophy: The FSHD clinical score.

Authors:  Costanza Lamperti; Greta Fabbri; Liliana Vercelli; Roberto D'Amico; Roberto Frusciante; Emanuela Bonifazi; Chiara Fiorillo; Carlo Borsato; Michelangelo Cao; Maura Servida; Francesca Greco; Rita Di Leo; Leda Volpi; Claudia Manzoli; Paola Cudia; Ebe Pastorello; Leopoldo Ricciardi; Gabriele Siciliano; Giuliana Galluzzi; Carmelo Rodolico; Lucio Santoro; Giuliano Tomelleri; Corrado Angelini; Enzo Ricci; Laura Palmucci; Maurizio Moggio; Rossella Tupler
Journal:  Muscle Nerve       Date:  2010-08       Impact factor: 3.217

7.  Early onset facioscapulohumeral muscular dystrophy.

Authors:  O F Brouwer; G W Padberg; E Bakker; C Wijmenga; R R Frants
Journal:  Muscle Nerve Suppl       Date:  1995

8.  Facioscapulohumeral muscular dystrophy: hearing loss and other atypical features of patients with large 4q35 deletions.

Authors:  C P Trevisan; E Pastorello; G Tomelleri; L Vercelli; C Bruno; S Scapolan; G Siciliano; F Comacchio
Journal:  Eur J Neurol       Date:  2008-12       Impact factor: 6.089

Review 9.  Facioscapulohumeral muscular dystrophy in early childhood.

Authors:  O F Brouwer; G W Padberg; C Wijmenga; R R Frants
Journal:  Arch Neurol       Date:  1994-04

10.  Low penetrance in facioscapulohumeral muscular dystrophy type 1 with large pathological D4Z4 alleles: a cross-sectional multicenter study.

Authors:  Emmanuelle Salort-Campana; Karine Nguyen; Rafaelle Bernard; Elisabeth Jouve; Guilhem Solé; Aleksandra Nadaj-Pakleza; Julien Niederhauser; Estelle Charles; Elisabeth Ollagnon; Françoise Bouhour; Sabrina Sacconi; Andoni Echaniz-Laguna; Claude Desnuelle; Christine Tranchant; Christophe Vial; Frederique Magdinier; Marc Bartoli; Marie-Christine Arne-Bes; Xavier Ferrer; Thierry Kuntzer; Nicolas Levy; Jean Pouget; Shahram Attarian
Journal:  Orphanet J Rare Dis       Date:  2015-01-21       Impact factor: 4.123

View more
  13 in total

Review 1.  Facioscapulohumeral muscular dystrophy (FSHD) molecular diagnosis: from traditional technology to the NGS era.

Authors:  Stefania Zampatti; Luca Colantoni; Claudia Strafella; Rosaria Maria Galota; Valerio Caputo; Giulia Campoli; Giulia Pagliaroli; Stefania Carboni; Julia Mela; Cristina Peconi; Stefano Gambardella; Raffaella Cascella; Emiliano Giardina
Journal:  Neurogenetics       Date:  2019-03-25       Impact factor: 2.660

2.  Predictors of functional outcomes in patients with facioscapulohumeral muscular dystrophy.

Authors:  Natalie K Katz; John Hogan; Ryan Delbango; Colin Cernik; Rabi Tawil; Jeffrey M Statland
Journal:  Brain       Date:  2021-12-16       Impact factor: 15.255

3.  Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene.

Authors:  Richard J L F Lemmers; Patrick J van der Vliet; Ana Blatnik; Judit Balog; Janez Zidar; Don Henderson; Rianne Goselink; Stephen J Tapscott; Nicol C Voermans; Rabi Tawil; George W A M Padberg; Baziel Gm van Engelen; Silvère M van der Maarel
Journal:  J Med Genet       Date:  2021-01-12       Impact factor: 6.318

Review 4.  Facioscapulohumeral muscular dystrophy-Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease.

Authors:  Sanne C C Vincenten; Nienke Van Der Stoep; Aimée D C Paulussen; Karlien Mul; Umesh A Badrising; Marjolein Kriek; Olivier W H Van Der Heijden; Baziel G M Van Engelen; Nicol C Voermans; Christine E M De Die-Smulders; Saskia Lassche
Journal:  Clin Genet       Date:  2021-08-01       Impact factor: 4.296

Review 5.  Facioscapulohumeral muscular dystrophy: genetics, gene activation and downstream signalling with regard to recent therapeutic approaches: an update.

Authors:  Teresa Schätzl; Lars Kaiser; Hans-Peter Deigner
Journal:  Orphanet J Rare Dis       Date:  2021-03-12       Impact factor: 4.123

6.  Prevalence and disease progression of genetically-confirmed facioscapulohumeral muscular dystrophy type 1 (FSHD1) in China between 2001 and 2020: a nationwide population-based study.

Authors:  Zhiqiang Wang; Liangliang Qiu; Minting Lin; Long Chen; Fuze Zheng; Lin Lin; Feng Lin; Zhixian Ye; Xiaodan Lin; Junjie He; Lili Wang; Xin Lin; Qifang He; Wanjin Chen; Yi Lin; Ying Fu; Ning Wang
Journal:  Lancet Reg Health West Pac       Date:  2021-11-22

7.  FSHD1 Diagnosis in a Russian Population Using a qPCR-Based Approach.

Authors:  Nikolay Vladimirovich Zernov; Anna Alekseevna Guskova; Mikhail Yurevich Skoblov
Journal:  Diagnostics (Basel)       Date:  2021-05-28

Review 8.  Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy.

Authors:  Anna Greco; Remko Goossens; Baziel van Engelen; Silvère M van der Maarel
Journal:  Clin Genet       Date:  2020-03-04       Impact factor: 4.438

Review 9.  Early-Onset Infantile Facioscapulohumeral Muscular Dystrophy: A Timely Review.

Authors:  Tai-Heng Chen; Yan-Zhang Wu; Yung-Hao Tseng
Journal:  Int J Mol Sci       Date:  2020-10-21       Impact factor: 5.923

10.  A 5-year clinical follow-up study from the Italian National Registry for FSHD.

Authors:  Liliana Vercelli; Fabiano Mele; Lucia Ruggiero; Francesco Sera; Silvia Tripodi; Giulia Ricci; Antonio Vallarola; Luisa Villa; Monica Govi; Louise Maranda; Antonio Di Muzio; Marina Scarlato; Elisabetta Bucci; Lorenzo Maggi; Carmelo Rodolico; Maurizio Moggio; Massimiliano Filosto; Giovanni Antonini; Stefano Previtali; Corrado Angelini; Angela Berardinelli; Elena Pegoraro; Gabriele Siciliano; Giuliano Tomelleri; Lucio Santoro; Tiziana Mongini; Rossella Tupler
Journal:  J Neurol       Date:  2020-08-19       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.